Pideka Group Inc. (CIMVF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pideka Group Inc. (CIMVF) trades at $0.0111 with AI Score 56/100 (Grade B). Pideka Group Inc. Market cap: $2.51M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for CIMVF: CIMVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CIMVF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CIMVF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Pideka Group Inc. (CIMVF) Healthcare & Pipeline Overview
Pideka Group Inc., operating as Ikänik Farms, is an integrated cannabis company focusing on cultivation, production, and distribution in California and Colombia. With a negative P/E ratio of -1.16 and a gross margin of 13.1%, the company competes in the specialty and generic drug manufacturing sector, offering products under the Ikanik, Essentials, Ronen, and Rations brands.
What Is the Investment Thesis for CIMVF?
Pideka Group Inc. (CIMVF) presents a speculative investment opportunity in the cannabis sector, characterized by high growth potential but also significant risks. With a current market capitalization of $2.51M and a negative P/E ratio of -1.16, the company's financial performance is under pressure, as reflected by a profit margin of -2220.5%. The company's gross margin stands at 13.1%. Key value drivers include expansion of its cultivation and production capabilities in Colombia, increased market penetration in California, and development of new cannabis-based products. Growth catalysts include evolving cannabis regulations in key markets and increasing consumer acceptance of cannabis products. However, potential risks include intense competition, regulatory uncertainties, and the company's current financial instability. Investors should carefully consider these factors before investing in CIMVF.
Based on FMP financials and quantitative analysis
CIMVF Key Highlights
- Market Cap of $2.51M indicates the company is a micro-cap stock with high growth potential but also higher risk.
- P/E Ratio of -1.16 reflects the company's current lack of profitability, requiring further analysis of its future earnings potential.
- Profit Margin of -2220.5% suggests significant operational challenges and the need for improved cost management.
- Gross Margin of 13.1% indicates the company's ability to generate revenue from sales after accounting for the cost of goods sold, but it needs to be improved.
- Beta of 0.57 suggests the stock is less volatile than the overall market, potentially offering some downside protection.
Who Are CIMVF's Competitors?
CIMVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.14 | +0.21% | $40.3M | 61 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| SHIEF Shield Therapeutics plc | $0.08 | +0.00% | $84.8M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CIMVF's Key Strengths?
- Vertically integrated operations.
- Focus on pharmaceutical-grade cannabinoids.
- Presence in both California and Colombia.
- Established brand portfolio.
What Are CIMVF's Weaknesses?
- Negative profitability.
- High operating expenses.
- Limited market share.
- Dependence on regulatory approvals.
What Could Drive CIMVF Stock Higher?
- Potential changes in cannabis regulations in key markets.
- Expansion of cultivation and production capabilities in Colombia.
- Increased market penetration in California.
- Development of new cannabis-based products.
What Are the Key Risks for CIMVF?
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Intense competition from other cannabis companies.
- Regulatory uncertainties and changes in cannabis laws.
- The company's current financial instability and negative profitability.
- Fluctuations in cannabis prices and market demand.
- Limited access to capital and financing options.
What Are the Growth Opportunities for CIMVF?
- Expansion of cultivation and production in Colombia: Colombia offers a favorable environment for cannabis cultivation due to its climate and lower production costs. Pideka Group Inc. can leverage this advantage to increase its production capacity and reduce costs, enhancing its competitiveness in the global cannabis market. The global cannabis market is projected to reach $47 billion by 2025, providing a substantial opportunity for growth. Timeline: Ongoing.
- Increased market penetration in California: California is one of the largest cannabis markets in the United States. Pideka Group Inc. can expand its presence in California by opening new dispensaries, increasing its distribution network, and developing new products tailored to the California market. The California cannabis market is projected to reach $7 billion by 2024. Timeline: Ongoing.
- Development of new cannabis-based products: Pideka Group Inc. can develop new cannabis-based products, such as edibles, beverages, and topicals, to cater to evolving consumer preferences. The market for cannabis-based products is growing rapidly, driven by increasing consumer demand for alternative consumption methods. The global cannabis edibles market is projected to reach $5 billion by 2025. Timeline: Ongoing.
- Strategic partnerships and acquisitions: Pideka Group Inc. can pursue strategic partnerships and acquisitions to expand its market reach, diversify its product portfolio, and gain access to new technologies. The cannabis industry is undergoing consolidation, with larger companies acquiring smaller players to gain scale and market share. Timeline: Ongoing.
- Expansion into international markets: Pideka Group Inc. can expand its operations into other international markets, such as Europe and Latin America, to capitalize on the growing global demand for cannabis products. The European cannabis market is projected to reach $3.9 billion by 2023, presenting a significant opportunity for growth. Timeline: Ongoing.
What Opportunities Does CIMVF Have?
- Expansion into new markets.
- Development of new products.
- Strategic partnerships and acquisitions.
- Increasing consumer acceptance of cannabis.
What Threats Does CIMVF Face?
- Intense competition.
- Regulatory uncertainties.
- Fluctuations in cannabis prices.
- Economic downturns.
What Are CIMVF's Competitive Advantages?
- Vertically integrated operations provide control over the supply chain.
- Focus on pharmaceutical-grade cannabinoids differentiates the company from competitors.
- Established presence in both California and Colombia provides access to key markets.
- Brand recognition through the Ikanik, Essentials, Ronen, and Rations brands.
What Does CIMVF Do?
Ikänik Farms, Inc., operating as Pideka Group Inc. (CIMVF), is a vertically integrated cannabis company with operations spanning cultivation, production, distribution, and dispensary management. Founded with the vision of becoming a leading provider of pharmaceutical-grade cannabinoids, the company has established a presence in both California and Colombia. Ikänik Farms offers a diverse product portfolio, including pharmaceutical-grade cannabinoids, decarboxylated flower, finished CBD products, and finished ingredient cannabis oil, catering to scientific and commercial markets. These products are marketed under the brands Ikanik, Essentials, Ronen, and Rations. The company's operations in California focus on distribution and dispensary management, leveraging the state's established cannabis market. In Colombia, Ikänik Farms concentrates on cultivation and production, taking advantage of the country's favorable climate and regulatory environment for cannabis cultivation. This dual-market strategy allows the company to serve both domestic and international demand for cannabis products. Pideka Group Inc. is headquartered in Toronto, Canada, reflecting its strategic focus on international cannabis markets and its commitment to regulatory compliance and quality standards. The company aims to differentiate itself through its focus on pharmaceutical-grade products and its integrated supply chain.
What Products and Services Does CIMVF Offer?
- Cultivates cannabis in Colombia.
- Produces pharmaceutical-grade cannabinoids.
- Manufactures decarboxylated flower.
- Creates finished CBD products.
- Develops finished ingredient cannabis oil.
- Distributes cannabis products in California and Colombia.
- Operates cannabis dispensaries in California.
How Does CIMVF Make Money?
- Cultivation and production of cannabis in Colombia.
- Distribution and sale of cannabis products in California and Colombia.
- Branding and marketing of cannabis products under the Ikanik, Essentials, Ronen, and Rations brands.
What Industry Does CIMVF Operate In?
Pideka Group Inc. operates within the rapidly evolving cannabis industry, which is experiencing significant growth driven by increasing legalization and acceptance of cannabis for both medical and recreational use. The market is characterized by intense competition, with numerous players vying for market share. Key trends include the development of new cannabis-based products, the expansion of retail dispensaries, and the increasing consolidation of cannabis companies. Pideka Group Inc. aims to differentiate itself through its focus on pharmaceutical-grade products and its integrated supply chain. Competitors include ACNNF (Acreage Holdings Inc.), CBDNF (Charlotte's Web Holdings, Inc.), DLTNF (Delta 9 Cannabis Inc.), EEVVF (EnWave Corporation), and EPWCF (Empower Clinics Inc.).
Who Are CIMVF's Key Customers?
- Scientific researchers requiring pharmaceutical-grade cannabinoids.
- Commercial businesses utilizing cannabis oil as an ingredient.
- Consumers purchasing cannabis products through dispensaries.
- Patients seeking medical cannabis products.
Key Financial Metrics
Its free cash flow yield is -3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.63 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -86.3%, the inverse of the P/E and a quick read on earnings relative to price.
Pideka Group Inc. (CIMVF) Valuation Context
Valued at $2.51M, CIMVF is classified as a micro-cap stock. Relative to its peer group, CIMVF's quantitative score of 56/100 is roughly in line with the peer average of 62/100.
Company Profile
Pideka Group Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Borja Sanz De Madrid. CIMVF has traded publicly since 2021.
F-Score 0/9Financial Health
Pideka Group Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CIMVF Financials
Bull Case vs Bear Case
Bull Case
- Vertically integrated operations.
- Focus on pharmaceutical-grade cannabinoids.
- Presence in both California and Colombia.
- Established brand portfolio.
Bear Case
- Negative profitability.
- High operating expenses.
- Limited market share.
- Dependence on regulatory approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CIMVF Latest News
No recent news available for CIMVF.
CIMVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CIMVF.
Price Targets
Wall Street price target analysis for CIMVF.
CIMVF MoonshotScore
What does this score mean?
The MoonshotScore rates CIMVF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Borja Sanz De Madrid
CEO
Borja Sanz De Madrid is the Chief Executive Officer of Pideka Group Inc. His background includes experience in international business development and corporate strategy. Prior to joining Pideka Group Inc., he held leadership positions in various multinational companies, focusing on market entry and expansion strategies. He has a strong understanding of the cannabis industry and a track record of driving growth in emerging markets. His expertise includes regulatory compliance, operational efficiency, and strategic partnerships.
Track Record: Since becoming CEO, Borja Sanz De Madrid has focused on streamlining operations and expanding the company's presence in key markets. Key achievements include securing strategic partnerships with distributors and increasing production capacity in Colombia. He has also overseen the development of new cannabis-based products and the expansion of the company's dispensary network in California.
CIMVF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pideka Group Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier carries higher risks compared to exchanges like NYSE or NASDAQ due to the lack of stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in CIMVF.
- Lower trading volume and wider bid-ask spreads can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the risk of fraud and manipulation.
- The company's financial stability is uncertain due to its negative profitability.
- The cannabis industry is subject to regulatory changes and uncertainties.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's competitive position in the cannabis market.
- Evaluate the company's regulatory compliance and risk management practices.
- Monitor the company's news releases and investor relations materials.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has established operations in both California and Colombia.
- The company has a portfolio of branded cannabis products.
- The company has a CEO with experience in international business development.
- The company is involved in the cultivation, production, and distribution of cannabis.
Pideka Group Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for CIMVF?
CIMVF holds an AI Score of 56/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Pideka Group Inc., operating as Ikänik Farms, is a cannabis company involved in cultivation, production, distribution, and dispensary operations in California and Colombia. The company offers a …
What does Pideka Group Inc. do?
Pideka Group Inc., operating as Ikänik Farms, is an integrated cannabis company involved in the cultivation, production, distribution, and dispensary operations in California and Colombia. The company focuses on providing pharmaceutical-grade cannabinoids, decarboxylated flower, finished CBD products, and finished ingredient cannabis oil for scientific and commercial sales.
What do analysts say about CIMVF stock?
As of 2026-03-17, formal analyst ratings for CIMVF (Pideka Group Inc.) are limited due to its OTC listing and micro-cap status. However, the company's potential lies in its integrated operations and presence in key cannabis markets like California and Colombia. Investors may want to evaluate the company's negative profitability, high competition, and regulatory risks.
What are the main risks for CIMVF?
The main risks for Pideka Group Inc. (CIMVF) include intense competition in the cannabis industry, regulatory uncertainties surrounding cannabis legalization and compliance, and the company's current financial instability, as evidenced by its negative profit margin. As an OTC-listed stock, CIMVF also faces liquidity risks and limited access to capital.
What are the key factors to evaluate for CIMVF?
Pideka Group Inc. (CIMVF) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does CIMVF data refresh on this page?
CIMVF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CIMVF's recent stock price performance?
Pideka Group Inc. (CIMVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Vertically integrated operations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CIMVF overvalued or undervalued right now?
Pideka Group Inc. (CIMVF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CIMVF before investing?
Before investing in Pideka Group Inc. (CIMVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- Analyst ratings are scarce due to the company's OTC listing.
- The cannabis industry is subject to rapid changes and regulatory uncertainties.